InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies.

We have established translational medicine and clinical teams at Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada and Australia. We have built up a novel and highly differentiable pipeline with intrinsic synergy through collaboration with partners, licensing-in, and independent discovery research and development. Our pipeline contains “First-in-Class NME” and “Best-in-Disease Combination” medicines, which enables InxMed to have significant impact on select types of tumors. InxMed prides itself on partnerships with well-known multinational pharmaceutical companies including Roche, Boehringer Ingelheim, and MSD, as well as many Chinese and global biotech companies. We always actively seek opportunities for collaboration with the goal to benefit patients.

InxMed management team members had senior R&D and commercial positions in top-ranking multinational companies, such as Roche, Novartis, MSD, Schering-Plough, GlaxoSmithKline, Johnson & Johnson and BeiGene. They have experience in leadingover a dozen of clinical development programs and new drug applications in China, including products such as Keytruda and Gardasil. They are experts in all aspects of innovative drug research, development, clinical translation, proof-of-concept validation, and marketing.